OncoTherapy ScienceTSE:4564 +5.00%50 PB Ratio is 3.76 as of Jul. 08, 2026, which is 20% below its 10-year median of 4.70. GuruFocus rates TSE:4564 with a GF Score™ of 50/100 and a GF Value™ of 円17.03 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,225 Biotechnology companies, OncoTherapy Science ranks worse than 59.67% on this metric.
OncoTherapy Science Inc stock PB Ratio (=3.58) is close to 5-year low of 3.4.
The historical rank and industry rank for OncoTherapy Science's PB Ratio or its related term are showing as below:
TSE:4564'
s PB Ratio Range Over the Past 10 Years
Min: 1.65 Med: 4.7 Max: 34.46
Current: 3.76
During the past 13 years, OncoTherapy Science's highest PB Ratio was 34.46. The lowest was 1.65. And the median was 4.70.
TSE:4564's PB Ratio is ranked worse than 59.67% of 1225
companies
in the Biotechnology industry
Industry Median: 2.92
vs TSE:4564: 3.76
During the past 12 months, OncoTherapy Science's average Book Value Per Share Growth Rate was 108.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -26.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -31.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of OncoTherapy Science was 7.90% per year. The lowest was -54.70% per year. And the median was -5.40% per year.
Back to Basics: PB Ratio
OncoTherapy Science (TSE:4564) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
OncoTherapy Science PB Ratio Related Terms
OncoTherapy Science PB Ratio Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, OncoTherapy Science's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's PB Ratio distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
OncoTherapy Science (TSE:4564) has a PB Ratio of 3.76 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on OncoTherapy Science and its competitors. This is 20% below median its historical median of 4.70. Over the past decade, OncoTherapy Science's PB Ratio has ranged from 1.65 to 34.46. According to the industry distribution chart, OncoTherapy Science ranks #731 out of 1225 companies in the Biotechnology industry, placing it in the top 59.7%.
Is OncoTherapy Science's PB Ratio too high?
OncoTherapy Science's current PB Ratio of 3.76 is 20% below median its 10-year median of 4.70. Over the past 10 years, this metric has ranged from a low of 1.65 to a high of 34.46. The Biotechnology industry median PB Ratio is 2.92. OncoTherapy Science's value of 3.76 is 28.8% above this industry median. Based on the distribution chart, OncoTherapy Science ranks #731 out of 1225 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #731 out of 1225 companies for PB Ratio. This places OncoTherapy Science in the lower half of its industry. The industry median PB Ratio is 2.92. OncoTherapy Science's value of 3.76 is 28.8% above this benchmark. Historically, OncoTherapy Science's own PB Ratio has ranged from 1.65 to 34.46 over the past decade. While the company's 10-year median is 4.70 vs. the industry median of 2.92, OncoTherapy Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,225 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoTherapy Science's current PB Ratio of 3.76 is 28.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on OncoTherapy Science and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoTherapy Science's current PB Ratio is 3.76, which is 20% below median its own 10-year median of 4.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円17.03, compared to a current price of 円21.00 — trading 23.3% above its estimated fair value. The current PB Ratio is 3.76, which is 20% below median its 10-year median of 4.70 and 28.8% above the Biotechnology industry median of 2.92. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current PB Ratio is 3.76 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (TSE:4564) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of 円21.00 is trading 23.3% above its estimated GF Value™ of 円17.03.
GuruFocus considers OncoTherapy Science to be Modestly Overvalued.
Key valuation signals for TSE:4564:
PB Ratio: 3.76 (20% below median its 10-year median of 4.70)
GF Value™: 円17.03 vs. price of 円21.00 (23.3% above fair value)
Industry Position: 28.8% above the Biotechnology median (#731 of 1225)
No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score
Get the complete analysis for TSE:4564
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4564 has been successfully added to your 
